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Abstract
Purpose The Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) has updated
its 2011 guidelines on the prevention of post-contrast acute kidney injury (PC-AKI). The results of the literature review and the
recommendations based on it, which were used to prepare the new guidelines, are presented in two papers.
Areas covered in part 1 Topics reviewed include the terminology used, the best way to measure eGFR, the definition of PC-AKI,
and the risk factors for PC-AKI, including whether the risk with intravenous and intra-arterial contrast medium differs.
Key Points
• PC-AKI is the preferred term for renal function deterioration after contrast medium.
• PC-AKI has many possible causes.
• The risk of AKI caused by intravascular contrast medium has been overstated.
• Important patient risk factors for PC-AKI are CKD and dehydration.
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Introduction
The Contrast Media Safety Committee (CMSC) of the
European Society of Urogenital Radiology (ESUR) produced
their most recent guidelines on what was then termed contrast
induced nephropathy (CIN) in 2011 [1]. Guidelines on the use
of contrast media (CM) in patients on dialysis and the use of
CM in diabetic patients using metformin were published in
2002 and 2014 [2, 3]. This review provides the information to
support the new CMSC guidelines, which were obtained
using a structured literature review based on clinical questions
and patient-intervention-comparator outcome (PICO) format-
ting. Since the literature related to the topics considered is so
large, the results of the review have been split into two papers.
The review only considers post-contrast kidney injury (PC-
AKI) after intravascular iodine-based CM. Acute kidney inju-
ry (AKI) is not associated with intravascular gadolinium-
based contrast agents in doses approved for clinical magnetic
resonance imaging.
In this first paper on PC-AKI, the following topics related
to diagnosis and risk are considered:
1. The clinical features and incidence of PC-AKI.
2. The choice of terms for renal function deterioration after
CM, the degree of renal function deterioration used to
diagnose PC-AKI, and the definitions of intravenous
and intra-arterial CM administration.
3. The reliability of the various equations used to measure
eGFR and the appropriate timing of eGFR measurement
before CM administration.
4. The evidence that CM can cause AKI, the levels of renal
function at which there is a risk of PC-AKI, and the recent
evidence suggesting that the risk of PC-AKImay be lower
after intravenous than after intra-arterial contrast medium.
5. The importance of the many risk factors for PC-AKI de-
scribed in the literature.
Recommendations are made for items 2–5. The recommen-
dations have been incorporated into version 10 of the ESUR
CMSC guidelines (see Table 4 in Part 2).
Clinical features and incidence of PC-AKI
The term PC-AKI is used to describe a decrease in renal func-
tion that follows intravascular administration of CM. The de-
crease in renal function is usually mild, peaking at 2–3 days,
and renal function usually returns to baseline values within 1–
3 weeks. Like all forms of AKI, an episode of PC-AKI is a
marker for increased short- and long-term morbidity and mor-
tality and prolonged hospital stay [4–10].
The risk of PC-AKI after intravenous (IV) CM has proba-
bly been overestimated. Two meta-analyses of 19,000 patients
who had received IV CM showed PC-AKI incidences of 6.4
% (95 % CI 5.0–8.1) and 5.0 % (95 % CI 3.8–6.5) [11, 12]. In
1 % of all patients the decline in renal function persisted for 2
months, but the weighted incidence of renal replacement ther-
apy (RRT) was as low as 0.06 % [11].
It has been suggested that intra-arterial (IA) CM adminis-
tration during catheter-based angiography, with or without
percutaneous coronary intervention (PCI), is associated with
a higher incidence of PC-AKI than IV CM administration [13,
14]. However, there are many causes of AKI following angi-
ography, and AKI may wrongly be attributed to the CM [15].
Catheter-based procedures may be complicated by haemody-
namic instability, and by embolization of cholesterol or throm-
bi to the renal arteries caused by catheter manipulations [16].
Any of these may lead to post-interventional AKI, which is
often misinterpreted as contrast-induced acute kidney injury
(CI-AKI) [17, 18]. A large meta-analysis of cardiovascular
outcomes after coronary angiography (CA) showed that the
association between PC-AKI and mortality was strongly con-
founded by baseline clinical features that predisposed to both
kidney injury and mortality [6]. The risk of PC-AKI reported
in studies adjusted for confounding features was much lower
than that from unadjusted studies. The incidence of AKI was
2.3 % and need for RRT 0.3 % in a recent retrospective anal-
ysis using propensity matching with controls of over 2,000
patients who had PCI [7].
Materials and methods
The guidelines were developed using the Appraisal of
Guidelines for Research and Evaluation (AGREE) II docu-
ment [19]. A guideline Writing Group (WG) prepared ten
clinical questions in Patient – Intervention – Comparison –
Outcome (PICO) format [20]. Systematic search strings were
developed with a professional librarian for four different bio-
medical literature databases (PubMed, Web of Science,
Embase, and the Cochrane Library). Language was limited
to English and German. Where necessary, additional system-
atic searches on specific topics, such as pediatric PC-AKI,
were performed.
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The titles and abstracts were screened for relevance and
selected on predefined in- and exclusion criteria. Emphasis
was put on comparative studies with strong scientific evidence,
such as meta-analyses and systematic reviews, and prospective
randomized controlled trials (RCTs). In addition, evidence was
collected from comparative cohort, patient-control and non-
comparative studies. Other important quality criteria were size
of population studied, duration of follow-up and control for
bias. Cross-referencing was used to find additional data. The
four systematic searches for paper 1 yielded 3,086 references,
of which 705were selected from their title and abstract. The full
texts of these 705 publications were reviewed and 105 were
selected for inclusion in this paper. The quality of evidence
was evaluated according to the Oxford Centre for Evidence
Based Medicine (OCEBM) 2011 levels of evidence: Grade
A: established scientific evidence; Grade B: scientific presump-
tion; Grade C: low level of evidence [21]. Where there was no
scientific evidence, recommendations were based on WG con-
sensus and graded as expert opinion (Grade D).
Other factors such as availability of techniques or expertise,
organizational consequences, financial costs and patient prefer-
ences were also considered. CM manuals and guidelines
(American College of Radiology (ACR), Royal Australian
and New Zealand College of Radiology (RANZCR), National
Institute for Health and Care Excellence (NICE), Royal College
of Radiologists (RCR), and Radiological Society of the
Netherlands (RSTN)) were consulted where appropriate.
The recommendations prepared by the WG are the result of
the available scientific evidence combined with these other
sources of information. They were discussed at the CMSC
meeting in Copenhagen, Denmark in February 2017 and the
text of the final recommendations and guidelines was subse-
quently approved by the academic members of the CMSC.
Once published in print, the validity of the CMSC guidelines
will be routinely set at 6 years. However, the CMSC members
constantly monitor the validity of the guidelines, and can pro-
pose revision at an earlier date if deemed necessary.
Results
QUESTION 1: What are the preferred terms
and definitions to be used in PC-AKI?
Terminology
Until recently there has not been a generally accepted term for
acute renal failure, which is a complex disorder withmany possi-
blecausesandrisk factors.Severalnephrologygroups, suchas the
Acute Dialysis Quality Initiative (ADQI) [22] and Kidney
Disease:ImprovingGlobalOutcome(KDIGO)[23],haveworked
on finding a suitable term. The Acute Kidney Injury Network
(AKIN), a group of experts in Critical Care and Nephrology,
suggested Acute Kidney Injury (AKI) as the preferred term for
acute renal failure to be used for all forms of AKI [24].
The CMSC recommends that the term PC-AKI should re-
place the older term of contrast-induced nephropathy (CIN) and
suggests using the terms recommended by the ACRCommittee
on Drugs and Contrast Media [25] when AKI follows CM
administration (Table 1). They state that post-contrast acute
kidney injury (PC-AKI) is a general term that should be used
if there is a sudden deterioration in renal function within 48 h of
the intravascular administration of iodine-based CM. They de-
scribe PC-AKI as a correlative diagnosis. They recommend
that the term contrast-induced acute kidney injury (CI-AKI) is
reserved for cases where a causal relation can be shown be-
tween the administered CM and the deterioration in renal func-
tion. However, in clinical practice it is usually difficult to dis-
tinguish CI-AKI from PC-AKI and very few of the published
studies have a suitable control group to allow the two condi-
tions to be separated. Thus, many cases of PC-AKI seen in
clinical practice or reported in clinical studies are likely to be
coincident to, but not caused by, CM administration.
Renal function definitions of PC-AKI
Thediagnosis ofPC-AKI isusuallybasedon surrogatemeasures
of absolute or relative change in serum creatinine (sCr), rather
than patient outcomes, such as renal failure, need for RRT or
mortality. The KDIGO Practice Guidelines [26, 27] adopted the
olderAKIN criteria [24] and recommended division ofAKI into
three stages dependent on sCr and/or urine output (Table 2).
The ESUR CMSC defined Contrast-Induced Nephropathy
(CIN) in their first survey-based guideline as “a condition in
which an impairment in renal function (an increase in sCr by
more than 25 % or 44 μmol/L, or 0.5 mg/dl) occurs within 3
days following the intravascular administration of a contrast
medium in the absence of an alternative aetiology” [28].
Multiple studies have shown that the incidence of PC-AKI
is largely dependent on the definition used [29–31]. A relative
increase in sCr of > 25 % has been the most sensitive indica-
tor, with absolute values being less sensitive. In coronary an-
giography studies, relative definitions had more prognostic
Table 1 PC-AKI: Terminology and definition
The preferred term for acute kidney injury associated with CM
administration when no control population is available is
Post-Contrast Acute Kidney Injury (PC-AKI). The term
Contrast-Induced Acute Kidney Injury (CI-AKI) should be used
only when comparison with a control allows CM to be shown
to be the cause of the acute kidney injury.
Level of Evidence D
PC-AKI and CI-AKI should be defined as an increase in sCr of ≥
0.3mg/dl, or of ≥ 1.5–1.9 times baseline (KDIGO definition of AKI)
in the 48–72 h following CM administration.
Level of Evidence C
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relevance [29]. In other studies, however, relative increases in
sCr were found to overestimate PC-AKI and absolute values
were considered preferable [32]. Relative values seem to be
more sensitive for patients with CKD 3B (eGFR 30–44 ml/
min/1.73m2) and CKD 2 (eGFR 60–89 ml/min//1.73m2), and
absolute values seem to be more sensitive for patients with
CKD 3A (eGFR 45–59 ml/min/1.73m2) [33, 34]. Studies in
critically ill populations using the AKIN definition found that
development of AKI correlated with ICU mortality [35].
The KDIGO criteria are more rigorously derived than the
CIN definition and are now being adopted as the standard for
PC-AKI studies [36]. The CMSC, like the European Renal
Best Practice (ERBP) working group, recommends that the
definition of PC- AKI (or CI-AKI) should use the KDIGO
definition of AKI: an increase in sCr of ≥ 0.3 mg/dl, or a sCr
increase of ≥ 1.5– 1.9 times baseline [37, 38] (Table 1). The
KDIGO recommendation is that the renal function change
should be within 48 h, but the CMSC recommends retaining
a period of 48–72 h after CM as being more practical for
diagnosing PC-AKI in radiological practice, the majority of
which involves outpatients.
Intravenous and direct and indirect intra-arterial CM
administration: definition of terms
The term intravenous CM administration indicates that CM
reaches the renal arteries after dilution by circulation through
the right heart and pulmonary circulation or a systemic capil-
lary bed.
The same is true for intra-arterial CM administration with
second-pass renal exposure, such as via catheters into the right
heart and pulmonary arteries and via catheters directly in the
carotid, subclavian, brachial, coronary andmesenteric arteries,
as well as into the infrarenal aorta and the iliac, femoral and
crural arteries. Note: Because of backflow during this type of
IA injection, small doses of CM may reach the kidney in a
relatively undiluted form.
The term intra-arterial CM administration with first-pass
renal exposure indicates that CM reaches the renal arteries dur-
ing its first pass in a relatively undiluted form, depending on the
distance of the site of injection from the renal arteries. This
occurs with injections through catheters into the left heart, the
thoracic and suprarenal abdominal aorta, and selectively into the
renal arteries. Note: In suprarenal aortic injections, some of the
injected CM escapes via suprarenal aortic side-branches and
reaches the kidney after dilution in the circulation.
QUESTION 2: What are the best equations for GFR
estimation in European populations?
Total glomerular filtration rate (GFR) is considered the best
overall index of kidney function, but cannot be measured eas-
ily in clinical practice, so GFR is estimated using sCr as an
endogenous filtration marker. In 1999, the Modification of
Diet in Renal Disease (MDRD) equation [39] was introduced
for estimating GFR. The quality of GFR estimates largely
depends on the accuracy of the creatinine measurements,
and should be based on sCr assays standardized to reference
methods [40]. The MDRD equation has therefore been re-
expressed for use with sCr assays standardized using isotope
dilution mass spectroscopy (IDMS) [41].
Table 2 Acute Kidney Injury Staging (KDIGO) and CKD-EPI and Schwartz Equations for calculating eGFR
(a) KDIGO staging for AKI
Stage Serum creatinine Urine output
1 sCr ≥ 0.3 mg/dl (≥ 26.5 μmol/L), or < 0.5 ml/kg/h for 6–12h
sCr increase of 1.5–1.9 x baseline
2 sCr increase of 2.0–2.9 x baseline < 0.5 ml/kg/h for ≥ 12h
3 sCr ≥ 4.0 mg/dl (≥ 354 μmol/L) or < 0.3 ml/kg/h for ≥ 24h
sCr increase > 3.0x baseline or Anuria for ≥ 12h
or need for renal replacement therapy
(b) CKD-EPI equation (sCr in μmol/L; age in years).
eGFR (ml/min/1.73 m2) =
Female sCr ≤ 62 μmol/L: 144 x (sCr / 62)-0.329 x 0.993Age
Female sCr > 62 μmol/L: 144 x (sCr / 62)-1.209 x 0.993Age
Male sCr ≤ 80 μmol/L: 141 x (sCr / 80)-0.411 x 0.993Age
Male sCr > 80 μmol/L: 141 x (sCr / 80)-1.209 x 0.993Age
All equations x 1.159 if African American race
(c) Revised Schwartz equation (sCr in μmol/L; patient length in cm).
eGFR (ml/min/1.73 m2) = 36.5 × Length / sCr
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In 2009, theCKD-EPI equationwasproposedby theChronic
Kidney Disease Epidemiology Collaboration (CKD-EPI), and
was shown to be superior to the MDRD equation, especially at
higher GFRs (Table 2) [42]. The National Kidney Foundation
recommended replacing the MDRD by the CKD-EPI equation
for routine clinical use [43]. The CMSC therefore recommends
the CKD-EPI equation for routine use in adults (Table 3). All
creatinine-basedequations shouldbeusedwith caution inpeople
with abnormally high or low muscle mass. Caution should also
beexercised inpatientswithAKI,because sCr takes several days
to stabilize andmay not reflect current GFR.
There are other equations for specific subgroups, such as
the Lund-Malmö (LM) revised equation for the Swedish
population [44], the Berlin Initiative Study (BIS-1) equa-
tion for the elderly German population [45], and the full age
spectrum (FAS) equation for children and adults [46].
However, these equations have not been validated in other
populations. Cystatin C equations for estimation of GFR
may have advantages over sCr-based equations but are lim-
ited by additional costs and lack of an international refer-
ence system for calibration [47].
Estimation of GFR in children
When estimating GFR in children, sCr levels should be mea-
sured by standardized reference methods because serum con-
centrations are lower than in adults [48]. The CMSC therefore
recommends the revised Schwartz equation for routine clinical
use in children (Table 3). The widely-used Schwartz equation
[49] was revised in 2009 to include the IDMS method and
plasma iohexol clearance as standardized reference methods
[50] (Tables 2 and 3).
A Cystatin C-based equation has been proposed that
showed the best accuracy (91 %) when combined with
height/SCr, height, sex and blood urea nitrogen (BUN) [49].
However, this requires an additional BUN, which lacks stan-
dardized measurement, and Cystatin C requires standardiza-
tion and calibration [51]. In children with increased muscle
mass both the sCr and Cystatin C based Schwartz formulas
tend to overestimate GFR.
Point-of-care creatinine measurements
Point-of-care (PoC) whole blood creatinine may be measured
with the older Jaffe (alkaline picrate) method or by enzymatic
methods, with the latter considered more accurate. Although
such measurements have practical advantages in patients
with increased risk of PC-AKI, PoC devices may lead to
overestimation of renal function in severe kidney failure
with resultant incorrect risk stratification [52]. Laboratory
professionals should be consulted about analytical perfor-
mance and quality assurance of whole blood PoC creati-
nine measurement.
For how long do GFR estimations remain valid?
There are no studies available on how long eGFR mea-
surements remain valid for estimating the PC-AKI risk.
The eGFR measurements can be regarded as stable in
individuals without CKD or underlying co-morbidities
such as heart failure or hypertension who are not taking
nephrotoxic drugs.
The CMSC considers eGFR measurements before intra-
vascular CM exposure valid for a maximum of:
(1) 7 days* if the patient
a) has an acute disease, an acute deterioration of a
known chronic disease or any other adverse event that
could have negatively influenced renal function
(eGFR), or
b) is a hospital inpatient
(2) 3 months
a) if the patient has a chronic disease with stable renal
function (eGFR), and
b) in all other patients (Table 3)
*Note: In patients with AKI, eGFR should be monitored
frequently, and a maximum of 1–2 days is advisable.
Table 3 Formulae for eGFR and timing of eGFR measurement
The CKD-EPI equation for estimated GFR (eGFR) is recommended
for adults. As with all creatinine-based eGFRs, results should be
interpreted with caution in people with abnormally high or low
muscle mass
Level of Evidence A
The revised Schwartz formula (2009) for eGFR is recommended for
children. As with all creatinine-based eGFRs, results should be
interpreted with caution in people with abnormally high or low
muscle mass
Level of Evidence C
eGFR is not reliable in patients with known AKI
Level of Evidence A
The CMSC considers eGFR measurements before intravascular
CM exposure valid for a maximum of:
1) 7 days* if the patient has (a) an acute disease, an acute deterioration
of a known chronic disease or any other adverse event that could
have negatively influenced renal function (eGFR), or (b) is a
hospital inpatient
2) 3 months (a) if the patient has a chronic disease with stable
renal function (eGFR) and (b) in all other patients
Level of Evidence D
*Note: in patients with AKI it is advisable to monitor eGFR frequently, so
a maximum of 1-2 days may be advisable.
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QUESTION 3: What is the evidence that contrast
media are truly a causative factor in AKI and what are
the eGFR values below which there is a risk of PC-AKI?
Contrast-induced nephropathy was accepted for many years,
but more recently it has been questioned whether CM causes
the deterioration in renal function that may occur after CM
administration [17, 53]. There are important limitations in
many studies that assess whether CM causes AKI. Most stud-
ies evaluate the use of IA CM in CA and/or percutaneous
coronary intervention (PCI) in patients with significant co-
morbidities and therefore may not be relevant for intravenous
administration, and most studies do not have adequate control
groups [54, 55].
Intravenous CM administration
There is controversy about the causal relationship be-
tween exposure to IV CM and PC-AKI, since there are
no prospective RCTs confirming this association [56, 57].
Without controlled studies, many factors such as diet, hy-
dration, physiological variation in sCr over time, and a
variety of nephrotoxic risk factors, including medications,
which may influence renal function, cannot be distin-
guished from any effect of the CM [17, 18, 58].
Although RCTs have the strongest research design for
assessing the effects of interventions, assessment of rare
conditions such as PC-AKI by RCT would require large
numbers of patients [53].
Based on comparisons of the relatively few studies
with and without control populations it has been sug-
gested that the risk of PC-AKI after IV CM has been
overestimated [53, 59]. A meta-analysis that retrospec-
tively studied 13 non-randomised controlled studies was
unable to find an increased incidence of AKI in patients
who received intravenous contrast medium [60].
Evidence from observational studies may need to be
used, despite the recognised methodological problems
[61]. Recently, a few large-scale studies using propensity
score (PS)-matching for the evaluation of PC-AKI in pa-
tients undergoing contrast-enhanced CT, which stratified
subjects according to their baseline sCr or eGFR, have
been published [62–65]. These studies were unable to
identify a risk of PC-AKI in patients with eGFR ≥ 30
ml/min/1.73m2, but there is conflicting evidence on
whether patients with severe renal impairment (eGFR
<30 ml/min/1.73m2) are at increased risk of PC-AKI
[63, 65]. Lack of information on hydration status was a
limitation in these studies, but when hydration status was
added to an improved PS model, the findings were similar
[66]. The failure to adjust for the various predictor vari-
ables in previous observational studies may explain the
differences between them and the recent PS matching-
based studies. Remaining major limitations of observa-
tional studies are the low numbers of patients with severe
renal impairment, and the variability of data available on,
for example, prophylactic volume expansion and the CM
dose administered.
Comparison of intra-arterial and intravenous CM
administration in the same patients
A limited number of studies have directly compared IV to IA
CM administration, using the patient as their own control. The
risk of PC-AKI as well as its clinical course was independent
of the route of administration in four retrospective studies of
patient populations with varying degrees of renal impairment
[67–70], and PC-AKI rates were similar to the rates for
unenhanced CT [70]. However, these studies suffer from
selection bias and procedures with IA CM administra-
tion with first- and second-pass renal exposure were not
separated.
Intra-arterial CM administration
The PC-AKI incidence following direct IACMadministration
with first-pass renal exposure is frequently reported to be
higher than after IV administration, but this remains contro-
versial [71, 72]. Problems with confounding factors are most
significant in studies on patients that undergo catheter-based
CA and/or PCI because it is impossible to separate the effects
of contrast media from the effects of co-morbidity, catheter
manipulations or other procedural variables. In large meta-
analyses on cardiovascular outcome the PC-AKI inci-
dence may have been strongly confounded by baseline
clinical characteristics, both for first- and second-pass IA
CM administration [6, 73]. Nonetheless, AKI in general
is a significant problem in these patients and is associat-
ed with increased morbidity, longer length of hospital
stay and higher cost [74], and may be associated with
mortality in a significant percentage of cardiac patients
[7]. Second-pass IA CM administration is considered to
have no higher risk than IV CM administration.
Since it is difficult to separate the effects of the proce-
dure from those of the CM, the CMSC decided, for opti-
mal safety, to choose a higher cut-off eGFR level for
preventive measures in patients undergoing catheter-
based diagnostic or interventional examinations using IA
CM administration with first-pass renal exposure, even
though some of the risk may relate to the procedure.
Also, the CMSC decided to include CA and/or PCI in this
category because these examinations frequently combine
IA CM administration with both first- and second-pass
renal exposure (Table 4).
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Special populations
There is limited evidence about PC-AKI in several special
populations, such as patients with renal or renal and pancreatic
transplants, or critically ill patients. In renal transplant recipi-
ents, the incidence of PC-AKI in patients receiving either IVor
IA CM was not higher than in patients without transplants,
and there was no graft loss or need for dialysis [75–77].
Critically ill patients in ICU with multi-organ disease have a
greater risk profile for AKI than other inpatients, and AKI
incidence varies with subpopulation, study design and hydra-
tion status [33, 78, 79]. Without properly controlled studies, it
is impossible to know the role of CM in causing the AKI.
Although earlier studies failed to show a role of CM [80,
81], a recent large PS-matched controlled study suggested an
increased PC-AKI risk for ICU patients with eGFR < 45 ml/
min/1.73m2 [82].
Paediatric PC-AKI
There are very few studies on paediatric PC-AKI [83–85]. As
the incidence of PC-AKI seems similar in children and ado-
lescents to that in adults, the CMSC considers that for optimal
safety the recommendations for sCr determination and pre-
vention of PC-AKI, which are predominantly based on studies
in adults (aged 18+ years), should also be used for children
and adolescents (Table 4).
QUESTION 4: What are the patient-
and procedure-related risk factors for developing
PC-AKI and which patient populations have a higher
risk for developing PC-AKI?
Patient-related risk factors
Impaired renal function is the most important patient risk fac-
tor for PC-AKI. Many meta-analyses and systematic reviews
of uncontrolled studies have identified a wealth of possible
clinical risk factors for AKI in general such as old age, female
gender, low BMI, classic cardiovascular and metabolic risk
factors, malignancy, inflammation, bleeding, anaemia and
hyperuricaemia [11, 12, 86–96]. However, uncontrolled stud-
ies cannot reliably differentiate baseline clinical risk factors
from effects attributable specifically to CM. In a meta-analysis
of controlled studies, no additional risk factors specific for
CM were demonstrated [60] (Table 4). The effect of two or
more risk factors is additive and increases the risk of PC-AKI.
Procedure-related risk factors: CM type and dose
A variety of risk factors have been related to the type of CM
and the way it is administered.
Multiple meta-analyses have shown no evidence that iso-
osmolar CM (IOCM) are associated with a significantly lower
rate of PC-AKI than non-ionic, low osmolar CM agents
(LOCM) [97–100]. However, the risk of PC-AKI is increased
when ionic, high-osmolar CM are used [101]. Repeated CM
administration within a short interval (48–72 h) has been
shown to increase the risk of PC-AKI [86] (Table 4).
Evidence about the influence of CM dose (CM volume x
CM concentration) indicates dependence on the route of ad-
ministration. There is insufficient evidence that dose is a prob-
lemwith IVCM.However, for direct IACM administration in
coronary angiographic intervention it is advisable to keep the
ratio of CM dose (in grams Iodine) to absolute eGFR (in ml/
min; corrected for body surface area) below 1.1 [102, 103] or
to keep the ratio of CM volume (in ml) to eGFR (in ml/min/
1.73m2) below 3.0 when using a CM concentration of 350
mgl/ml [104, 105] (Table 4).
Table 4 Risk of PC-AKI
(a) Levels of eGFR at which there is a risk
The risk of PC-AKI in patients with eGFR ≥ 30 ml/min/1.73m2 after
intravenous and intra-arterial CM administration with second-pass
renal exposure is very low, but there is conflicting evidence on the risk
for intra-arterial CM administration with first-pass renal exposure
Level of Evidence: B
Preventive measures are recommended for patients with eGFR < 30
ml/min/1.73m2 before intravenous and intra-arterial CM
administration with second-pass renal exposure
Level of Evidence: C
Preventive measures are recommended for patients with eGFR < 45
ml/min/1.73m2 if they are in ICU or if they will receive intra-arterial
CM administration with first-pass renal exposure
Level of Evidence: C
Recommendations for prevention of PC-AKI in adults may also be used
in children and adolescents
Level of Evidence D
(b) Risk factors
The principal risk factor for PC-AKI is impaired renal function. Most
other published patient-related risk factors are risk factors for the
presence of chronic kidney disease or AKI, and are not specific for
PC-AKI
Level of Evidence B
There is no difference in PC-AKI risk between IOCM and LOCM. The
use of ionic, high-osmolar CM and repeated CM injections in a short
period (48–72 h) should be avoided
Level of Evidence C
When CM are injected intravenously, there is insufficient evidence that
CM dose is a risk factor. When CM are injected intra-arterially, the
ratio of CM dose (in gram Iodine) / absolute eGFR (in ml/min) should
be kept below 1.1 or the ratio of CM volume (in ml) / eGFR (in
ml/min/1.73m2) should be kept below 3.0 when using a CM
concentration of 350 mgl/ml
Level of Evidence C
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Conclusion
PC-AKI has been adopted as the best term to apply to renal
function deterioration after intravascular CM administration
because, unlike some of the older terms, it does not imply that
CM is the cause. Stage 1 of the KDIGO classification of AKI
is recommended as the change in renal function used to diag-
nose PC-AKI. The principal risk factor for PC-AKI is im-
paired renal function, and the recommended ways to measure
this are by the CKD-EPI equation in adults and the Schwartz
equation in children. In recent years, it has become apparent
that the risk of true CI-AKI was overstated in the past. When
properly corrected for the many other possible causes of AKI
in patients with chronic kidney disease, the risk of CI-AKI
when modern low osmolar CM are administered IV or IA is
low. Repeated CM administration within a 24- to 48-h period
increases the risk of CI-AKI. The evidence of a higher risk
with IA than with IV CM administration is limited, but the
CMSC nonetheless considers that the cut-off levels of eGFR
used to indicate the need for prophylaxis before IA adminis-
tration with first-pass renal exposure should be stricter, and
that there should be a maximum volume of CM given intra-
arterially during any examination or procedure with first-pass
renal exposure.
The recommendations made in this paper have been incor-
porated into the ESURCMSC guidelines (see Table 4, Part 2).
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